Publikasi Scopus 2024 per tanggal 30 November 2024 (994 artikel)

Harahap A.S.; Roren R.S.; Imtiyaz S.
Harahap, Agnes Stephanie (57218511857); Roren, Regina Stefani (57224893129); Imtiyaz, Shofiyya (57814993800)
57218511857; 57224893129; 57814993800
A Comprehensive Review and Insights into the New Entity of Differentiated High-Grade Thyroid Carcinoma
2024
Current Oncology
31
6
3311
3328
17
1
Department of Anatomical Pathology, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia
Harahap A.S., Department of Anatomical Pathology, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Roren R.S., Department of Anatomical Pathology, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia; Imtiyaz S., Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia
Differentiated high-grade thyroid carcinoma (DHGTC) is a new subset within the spectrum of thyroid malignancies. This review aims to provide a comprehensive overview of DHGTC, focusing on its historical perspective, diagnosis, clinical characteristics, molecular profiles, management, and prognosis. DHGTC demonstrates an intermediate prognosis that falls between well-differentiated thyroid carcinoma and anaplastic thyroid carcinoma. Previously unenumerated, this entity is now recognized for its significant impact. Patients with DHGTC often present at an older age with advanced disease and exhibit aggressive clinical behavior. Molecularly, DHGTC shares similarities with other thyroid malignancies, harboring driver mutations such as BRAFV600E and RAS, along with additional late mutations. The unique behavior and histologic features of DHGTC underscore the necessity of precise classification for prognostication and treatment selection. This highlights the critical importance of accurate diagnosis and recognition by pathologists to enrich future research on this entity further. © 2024 by the authors.
high-grade; poorly differentiated; thyroid carcinoma; well-differentiated
Humans; Mutation; Neoplasm Grading; Prognosis; Thyroid Neoplasms; B Raf kinase; K ras protein; Ki 67 antigen; thyroglobulin; anaplastic thyroid carcinoma; cancer chemotherapy; cancer grading; cell differentiation; cytopathology; diagnostic test accuracy study; differentiated thyroid cancer; drug therapy; echography; external beam radiotherapy; fibrosis; histology; human; immunohistochemistry; papillary thyroid carcinoma cell; positron emission tomography-computed tomography; predictive value; Review; scintigraphy; sensitivity and sensibility; thyroid cancer; thyroid carcinoma; cancer grading; classification; genetics; mutation; pathology; prognosis; therapy; thyroid tumor
Multidisciplinary Digital Publishing Institute (MDPI)
17187729
38920735
Review
Q2
868
5516